Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease

Next Previous
Trial Profile

A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Adalimumab
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SEAVUE
  • Sponsors Janssen; Janssen-Cilag

Most Recent Events

  • 08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
  • 17 Oct 2023 Results assessing key inflammatory mediators in CD associated with the MoA of UST and ADA in the context of a head-to-head comparator study , presented at the 31st United European Gastroenterology Week
  • 27 Oct 2021 Results assessing the assess the effects of ustekinumab and adalimumab on health-related quality of life in biologic-naive patients with Crohn's Disease, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top